Cargando…

IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry

BACKGROUND: The relative contribution of isocitrate dehydrogenase mutations (mIDH) and O6-methylguanine-DNA methyltransferase promoter methylation (methMGMT) as biomarkers in glioblastoma remain poorly understood. METHODS: We investigated the association between methMGMT and mIDH with progression fr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Pei, Zhang, Wei, Wang, Yinyan, Peng, Xiaoxia, Chen, Baoshi, Qiu, Xiaoguang, Li, Guilin, Li, Shouwei, Wu, Chenxing, Yao, Kun, Li, Wenbin, Yan, Wei, Li, Jie, You, Yongping, Chen, Clark C., Jiang, Tao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747376/ https://www.ncbi.nlm.nih.gov/pubmed/26503470

Ejemplares similares

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

Radiation combined with temozolomide contraindicated for young adults diagnosed with anaplastic glioma
por: Yang, Pei, et al.
Publicado: (2016)

XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
por: Le, Nguyen Quoc Khanh, et al.
Publicado: (2020)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

Predictive MGMT status in a homogeneous cohort of IDH wildtype glioblastoma patients
por: Radke, Josefine, et al.
Publicado: (2019)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
por: Mareike, Müller, et al.
Publicado: (2021)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
por: Incekara, Fatih, et al.
Publicado: (2020)

Immune-Related lncRNA Risk Signatures Predict Survival of IDH Wild-Type and MGMT Promoter Unmethylated Glioblastoma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic impact of PDGFRA gain/amplification and MGMT promoter methylation status in patients with IDH wild-type glioblastoma
por: Higa, Nayuta, et al.
Publicado: (2022)

The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
por: Incekara, Fatih, et al.
Publicado: (2020)

Case report: tumor-treating fields prolongs IDH-mutant anaplastic astrocytoma progression-free survival and pathological evolution to glioblastoma
por: Lin, Yi, et al.
Publicado: (2021)

Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status
por: Wang, Ke, et al.
Publicado: (2021)

Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?
por: Combs, Stephanie E, et al.
Publicado: (2011)

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma
por: Schiffgens, Salveena, et al.
Publicado: (2016)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma
por: Wu, Chenxing, et al.
Publicado: (2020)

Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
por: Teske, Nico, et al.
Publicado: (2021)

The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents
por: Kurdi, Maher, et al.
Publicado: (2021)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients
por: Ye, Ningrong, et al.
Publicado: (2019)

Prognostic role and interaction of TERT promoter status, telomere length and MGMT promoter methylation in newly diagnosed IDH wild-type glioblastoma patients
por: Giunco, S., et al.
Publicado: (2023)

LTBP1 plays a potential bridge between depressive disorder and glioblastoma
por: Fu, Xiaojun, et al.
Publicado: (2020)

Correction to: LTBP1 plays a potential bridge between depressive disorder and glioblastoma
por: Fu, Xiaojun, et al.
Publicado: (2020)

Clinical strategies to manage adult glioblastoma patients without MGMT hypermethylation
por: Liu, Delin, et al.
Publicado: (2022)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Immunohistochemical Expression of PD-L1 and IDH1 with Detection of MGMT Promoter Methylation in Astrocytoma
por: Hareedy, Amal Ahmed, et al.
Publicado: (2022)

ADC, D, f dataset calculated through the simplified IVIM model, with MGMT promoter methylation, age, and ECOG, in 38 patients with wildtype IDH glioblastoma
por: Maralani, Pejman Jabehdar, et al.
Publicado: (2021)

Improved risk stratification in younger IDH wild-type glioblastoma patients by combining a 4-miRNA signature with MGMT promoter methylation status
por: Unger, Kristian, et al.
Publicado: (2020)

Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data
por: Krigers, Aleksandrs, et al.
Publicado: (2022)

Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status
por: Tini, Paolo, et al.
Publicado: (2023)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
por: Chen, Wei-jun, et al.
Publicado: (2020)

The value of MGMT promote methylation and IDH-1 mutation on diagnosis of pseudoprogression in patients with high-grade glioma: A meta-analysis
por: Zhou, Min, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lg3riejrvf5s4pssb765ldcgi5